Dr. Packard received his Bachelor’s Degree in chemistry from the University of New Hampshire, where he did undergraduate research in chemical oceanography, and his PhD in inorganic chemistry from Colorado State University, where he studied Jahn-Teller distortions in copper complexes. His first exposure to nuclear medicine was as a postdoctoral fellow at the University of Cincinnati where he prepared the first chemically well-defined ⁹⁹Tc complexes of aminopolycarboxylate ligands (e.g., EDTA). This was followed by two years as an Assistant Scientist at Brookhaven National Laboratory where he continued his investigations into technetium chemistry. He then moved to Boston Children’s Hospital where he is now a Sr. Research Associate in Nuclear Medicine and Director of Radiopharmaceutical Research and an Associate Professor Radiology at Harvard Medical School. His research interests still include radiometals, but have shifted from ^99mTc to ^64/67Cu- and ⁸⁹Zr-labeled proteins and now also include ¹⁸F chemistry where his research is primarily focused on the development of an¹⁸F-labeled myocardial perfusion agent.